PDF(Pubmed)
Abstract：
UNASSIGNED: Japan has experienced 8 waves of the coronavirus disease 2019 (COVID-19) outbreak over the past 3 years, resulting in an increasing number of deaths and incidence of severe infections. This study aimed to analyze the data from the Japanese inflammatory bowel disease (IBD) patients with COVID-19 registry (J-COSMOS) up to the eighth wave to investigate the clinical course of IBD patients with COVID-19 and factors contributing to disease severity.
UNASSIGNED: In this multicenter, observational, cohort study, we analyzed a cohort of 1308 IBD patients diagnosed with COVID-19, enrolled across 77 participating facilities in the J-COSMOS registry from June 2020 to December 2022. Data on age, sex, IBD (classification, treatment, and activity), and COVID-19 (symptoms, severity, and treatment) were analyzed.
UNASSIGNED: The majority of patients (76%) were in clinical remission. According to the World Health Organization classification of COVID-19 severity, 98.4% of IBD patients had nonsevere disease, while 1.6% of patients had severe or critical disease. COVID-19 did not affect disease activity in most IBD patients. Stepwise logistic regression analysis revealed that high body mass index, and cerebrovascular disease were risk factors for severe COVID-19. Corticosteroids could affect COVID-19 severity, whereas anti-tumor necrosis factor α antibodies and thiopurines were associated with a reduced risk of severe COVID-19. No deaths were observed among IBD patients with COVID-19 registered in this cohort.
UNASSIGNED: The impact of COVID-19 on IBD disease activity and factors associated with COVID-19 severity were consistent with findings of previous reports. No deaths in Japanese patients with IBD were observed.
UNASSIGNED: In this multicenter, observational, cohort study, we analyzed a cohort of 1308 IBD patients diagnosed with COVID-19, enrolled across 77 participating facilities in the J-COSMOS registry from June 2020 to December 2022. Data on age, sex, IBD (classification, treatment, and activity), and COVID-19 (symptoms, severity, and treatment) were analyzed.
UNASSIGNED: The majority of patients (76%) were in clinical remission. According to the World Health Organization classification of COVID-19 severity, 98.4% of IBD patients had nonsevere disease, while 1.6% of patients had severe or critical disease. COVID-19 did not affect disease activity in most IBD patients. Stepwise logistic regression analysis revealed that high body mass index, and cerebrovascular disease were risk factors for severe COVID-19. Corticosteroids could affect COVID-19 severity, whereas anti-tumor necrosis factor α antibodies and thiopurines were associated with a reduced risk of severe COVID-19. No deaths were observed among IBD patients with COVID-19 registered in this cohort.
UNASSIGNED: The impact of COVID-19 on IBD disease activity and factors associated with COVID-19 severity were consistent with findings of previous reports. No deaths in Japanese patients with IBD were observed.
摘要：
■日本在过去3年中经历了8波2019年冠状病毒病（COVID-19）爆发，导致越来越多的死亡和严重感染的发生率。本研究旨在分析来自日本炎症性肠病（IBD）的COVID-19注册（J-COSMOS）患者的数据，直至第八波，以调查IBD患者的临床病程以及影响疾病严重程度的因素。
■在这个多中心中，观察,队列研究,我们分析了2020年6月至2022年12月在J-COSMOS注册中心的77个参与机构中纳入的1308例确诊为COVID-19的IBD患者队列.年龄数据,性别,IBD(分类，治疗,和活动)，和COVID-19（症状，严重程度,和治疗）进行分析。
■大多数患者（76％）处于临床缓解期。根据世界卫生组织对COVID-19严重程度的分类，98.4%的IBD患者患有非严重疾病，而1.6%的患者患有严重或危重疾病。COVID-19对大多数IBD患者的疾病活动性没有影响。逐步Logistic回归分析显示，高体重指数，脑血管疾病是严重COVID-19的危险因素。皮质类固醇可影响COVID-19的严重程度，而抗肿瘤坏死因子α抗体和硫嘌呤与严重COVID-19的风险降低相关。在该队列中登记的患有COVID-19的IBD患者中未观察到死亡。
■COVID-19对IBD疾病活动性的影响以及与COVID-19严重程度相关的因素与以前报告的结果一致。日本IBD患者没有死亡。
■在这个多中心中，观察,队列研究,我们分析了2020年6月至2022年12月在J-COSMOS注册中心的77个参与机构中纳入的1308例确诊为COVID-19的IBD患者队列.年龄数据,性别,IBD(分类，治疗,和活动)，和COVID-19（症状，严重程度,和治疗）进行分析。
■大多数患者（76％）处于临床缓解期。根据世界卫生组织对COVID-19严重程度的分类，98.4%的IBD患者患有非严重疾病，而1.6%的患者患有严重或危重疾病。COVID-19对大多数IBD患者的疾病活动性没有影响。逐步Logistic回归分析显示，高体重指数，脑血管疾病是严重COVID-19的危险因素。皮质类固醇可影响COVID-19的严重程度，而抗肿瘤坏死因子α抗体和硫嘌呤与严重COVID-19的风险降低相关。在该队列中登记的患有COVID-19的IBD患者中未观察到死亡。
■COVID-19对IBD疾病活动性的影响以及与COVID-19严重程度相关的因素与以前报告的结果一致。日本IBD患者没有死亡。
